Search

Displaying results 4841 - 4850 of 7540 in total
  1. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758]. … As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].

  2. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  3. Drug

    Fenoxaprop-ethyl

    go.drugbank.com/drugs/DB05252
    Experimental

    Fenoxaprop-ethyl has been investigated to treat chronic angina, the chest pain that occurs from inadequate blood flow to the coronary arteries around the heart. … Fenoxaprop-ethyl (organic nitrate combined with L-arginine), is an oral proprietary nitrate therapeutic shown to induce coronary vasodilation while overcoming the significant problem of drug tolerance.

  4. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.

  5. Drug

    Washed Microbiota Transplantation

    go.drugbank.com/drugs/DB15745
    Investigational

    Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic purification system combined with repeated centrifugation and … The resulting suspension is shown to decrease FMT-related adverse events.

  6. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.

  7. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012. … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant

  8. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by

  9. Drug

    VIR201

    go.drugbank.com/drugs/DB05110
    Experimental

    The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.

  10. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume